Side effects and toxicities of targeted therapies in stage IV melanoma

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Melanoma incidence is rising globally, necessitating novel therapeutic strategies for advanced stages.
• Current research focuses on emerging treatments for stage IV melanoma, addressing their associated toxicities.

Purpose of the Study:

• To review the toxicity profiles of new treatments for advanced melanoma.
• To categorize and describe the adverse events associated with targeted tyrosine kinase inhibitors and immunomodulatory agents.

Main Methods:

• Literature review of recent studies on advanced melanoma treatments.
• Analysis of reported toxicities for targeted tyrosine kinase inhibitors and immunomodulatory agents.

Main Results:

• Targeted tyrosine kinase inhibitors commonly cause fatigue.
• Immunomodulatory agents are associated with immune-related adverse events (irAEs).
• Both drug classes demonstrate therapeutic potential despite their distinct toxicity patterns.

Conclusions:

• New melanoma therapies offer hope for stage IV disease management.
• Understanding and managing treatment-specific toxicities is crucial for successful outcomes.
• Novel combination therapies are likely key to future melanoma treatment advancements.